Quick Takeaways
- Commodore Capital LP filed SCHEDULE 13G/A for Vistagen Therapeutics, Inc. Common Stock, par value $0.001 per share (VTGN).
- Disclosed ownership: 9.9%.
- Date of event: 31 Dec 2025.
Commodore Capital LP - 31 Dec 2025 SCHEDULE 13G/A Report for Vistagen Therapeutics, Inc. Common Stock, par value $0.001 per share (VTGN)
- Filing Manager
- Commodore Capital LP
- Reporting Manager
- Commodore Capital LP
- Symbol
- VTGN
- Shares outstanding
- 44,277,859 shares
- Disclosed Ownership
- 4,383,508 shares
- Ownership
- 9.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Feb 2026, 16:26:03 UTC
- Date of event
- 31 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Commodore Capital LP disclosed 9.9% ownership in Vistagen Therapeutics, Inc. Common Stock, par value $0.001 per share (VTGN) on 31 Dec 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Feb 2026, 16:26.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 9.9% | 4,383,508 | 0 | 4,383,508 | Michael Kramarz | Managing Partner | |
| Commodore Capital Master LP | 9.9% | 4,383,508 | 0 | 4,383,508 | Michael Kramarz | Authorized Signatory | |
| Robert Egen Atkinson | 9.9% | 4,383,508 | 0 | 4,383,508 | Robert Egen Atkinson | Authorized Signatory | |
| Michael Kramarz | 9.9% | 4,383,508 | 0 | 4,383,508 | Michael Kramarz | Authorized Signatory |